

FINDING OF NO SIGNIFICANT IMPACT

for

Trexonil™ (Naltrexone HCl)  
For Use in Cervidae

Wildlife Pharmaceuticals  
Fort Collins, Colorado

The Center for Veterinary Medicine has carefully considered the potential environmental impact of this action and has concluded that this action will not have a significant effect on the quality of the human environment. Therefore, an environmental impact statement will not be required.

Wildlife Pharmaceuticals has submitted the attached environmental assessment (EA) dated September 13, 1993, for Trexonil™ (naltrexone HCl) to be used as an antagonist to carfentanil sedation in free ranging or confined members of the family cervidae.

Wildlife Pharmaceuticals manufactures and distributes the finished product.

The September 13, 1993, EA adequately addresses environmental and occupational safety and provides a statement of compliance with applicable Federal, state, and local environmental and occupational laws.

The information provided in the Wildlife Pharmaceuticals EA is adequate to determine that the manufacture of the product is not expected to have a significant impact on the human environment.

10/21/96  
Date

R. C. Livingston  
Director, Office of New Animal Drug Evaluation, HFV-100

Attachments: Environmental Assessment dated September 13, 1993